Androski Lindsay 4

4 · Arbutus Biopharma Corp · Filed Feb 2, 2026

AI-generated summary of this filing

Updated Feb 3, 2026

Arbutus (ABUS) CEO Lindsay Androski Receives RSU and Option Awards

What Happened

Lindsay Androski, President & CEO and Director of Arbutus Biopharma (ABUS), received equity awards on 2026-02-02 totaling 99,700 shares: 28,000 restricted stock units (RSUs) and a 71,700-share derivative award (option). The grants were awarded at $0.00 (no cash purchase). These are compensation awards, not open-market purchases or sales.

Key Details

Transaction date: 2026-02-02; reported same day (timely filing).
Award amounts: 28,000 RSUs (F1) and 71,700 derivative/option shares (listed as derivative).
Vesting: RSUs vest in three equal annual installments beginning one year from the grant date (F1). The option/derivative vests over four years at 1/48th per month starting one month after the grant (F3).
Tax withholding: On each RSU vesting date, common shares will be automatically sold to cover tax withholding in a non-discretionary "sell-to-cover" transaction (F1).
Price note: The grants are reported at $0.00; F2 in the filing references the Nasdaq closing price on the grant date but the numeric closing price is not provided in the excerpt.
Shares owned after transaction: Not specified in the provided filing excerpt.
Filing timeliness: Reported on the same date as the transactions; no late filing indicated.

Context

RSUs are a contingent right to receive shares at vesting (common executive compensation); the option award is a derivative that vests over time and must be exercised to convert to shares. Automatic sales to cover taxes are routine and do not necessarily indicate a change in insider sentiment. These awards increase potential future insider ownership as they vest, but are standard long-term incentive compensation rather than open-market buying.

Form 4

Period: 2026-02-02

DirectorPresident and CEO

Transactions

Award
Common Shares
[F1]
2026-02-02+28,000→ 28,000 total
Award
Stock Option (Right to Buy)
[F2][F3]
2026-02-02+71,700→ 71,700 total
Exercise: $4.39Exp: 2036-02-02→ Common Shares (71,700 underlying)

Footnotes (3)

[F1]Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.
[F2]Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
[F3]This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.

Signature

/s/ Tuan Nguyen as attorney-in-fact for Lindsay Androski|2026-02-02

1 file